Roginolisib Cancer Treatment Trial Results Reported
The drug showed a median survival of 20.8 months in a Phase 1 study of patients with advanced solid and hematologic malignancies.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Should developers prioritize creating new cancer drugs for rare solid tumor indications?
iOnctura has released findings from its Phase 1 clinical trial for roginolisib, a PI3K delta inhibitor tested on 44 patients with advanced malignancies. The study notably highlights the potential of this drug for treating uveal melanoma.
Why it matters
The company is targeting PI3K delta because no inhibitors for this enzyme are currently approved for solid tumors, providing a potential new treatment pathway for patients with uveal melanoma where immunosuppression drives the disease.
The Phase 1 study enrolled 44 patients, including a 24-patient dose-escalation phase and a 20-patient expansion cohort. Only three patients experienced grade 3 adverse events, and investigators reported no dose-limiting toxicities.
The players
iOnctura
This biotechnology company focuses on developing small molecule therapies to treat cancer and was established as a spinout from a partnership with Merck KGaA.
Merck KGaA
A German multinational science and technology company that provided the original partnership foundation for the formation of iOnctura.
The details
Roginolisib functions as an oral conformation stabilizer that binds to a unique site in the inactive state of PI3K delta, preventing ATP binding and enzyme activation. In head-to-head comparisons, the compound outperformed Zydelig in reducing cancer signaling pathway effectors.
Timeline
iOnctura spun out of a partnership with Merck KGaA in 2017.
The clinical trial results were published on October 14, 2026.
The Big Picture
This study follows the established research objective of the PI3K delta signaling pathway inhibition strategy by seeking to address the lack of solid tumor treatment approvals for this target.
The reported results provide a proof-of-concept for a new class of inhibitors that could eventually offer a different treatment profile for advanced cancer patients. Continued clinical development will determine whether this drug can become a viable option compared to current standard immunotherapies.
The takeaway
Roginolisib demonstrates that targeting PI3K delta through conformation stabilization may offer a cleaner toxicity profile than existing inhibitors. Researchers will monitor future trials to see if this efficacy advantage holds as patient cohorts expand.
Further reading
For more on the current development landscape, visit the Cancer section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Should developers prioritize creating new cancer drugs for rare solid tumor indications?
